全球右美沙芬市场 – 行业趋势和 2030 年预测

右美沙芬市场分析和规模

预计全球右美沙芬市场将在预测期内快速增长。咳嗽是上呼吸道和下呼吸道感染的典型症状。根据美国国家生物技术信息中心 2014 年发布的数据，咳嗽是全球就诊初级保健医生的最常见原因，约占所有就诊的 8%。根据同一来源，全球普通人群咳嗽的年患病率估计在 10% 至 33% 之间。

Data Bridge Market Research 分析称，2022 年全球右美沙芬市场规模为 4.8725 亿美元，预计到 2030 年将达到 5.8731 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 4.8%。由于对此类产品的需求量很大，“非处方 (OTC)”在全球右美沙芬市场的产品类型细分市场中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

右美沙芬市场范围和细分

Market Definition

Dextromethorphan is a cough suppressant. It's sold separately over-the-counter, but it's also found in a lot of over-the-counter and prescription combination drugs. It has an effect on the brain signals that cause cough reflexes. It is a reflex response to the tracheobronchial tree's chemical, mechanical, or inflammatory irritation, which is transmitted reflexively through neurons in the brainstem by sensory neurons in the airways.

Dextromethorphan Market Dynamics

Drivers

• Increasing Prevalence of Cough Related Conditions

Dextromethorphan is commonly used as an over-the-counter cough suppressant. The rising prevalence of respiratory conditions such as the common cold, flu, bronchitis, and allergies has led to an increased demand for cough medications, driving the growth of the global dextromethorphan market.

• Growing Consumer Awareness and Self Medication

With increased access to healthcare information and self-medication practices, consumers are becoming more aware of over-the-counter medications such as Dextromethorphan. As a result, individuals are more likely to seek relief from cough symptoms by purchasing Dextromethorphan-containing products, contributing to market growth.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion of the Pharmaceutical Industry

The pharmaceutical industry is experiencing growth due to various factors, including advancements in drug development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the global dextromethorphan market as it is widely used in cough and cold medications.

• Technological Advancements in Drug Delivery Systems

Innovations in drug delivery systems, such as improved formulations, extended-release formulations, and combination products, have enhanced the efficacy and convenience of cough medications containing dextromethorphan. These advancements attract consumers and contribute to market expansion.​​​​​​​

Restraints/Challenges

• Rising Competition

The global dextromethorphan market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.

• Side Effects and Safety Concerns

Dextromethorphan, like any medication, can have potential side effects or adverse reactions. Safety concerns, especially when used in high doses or in combination with other substances, can impact consumer confidence and create challenges for market growth.

This global dextromethorphan market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dextromethorphan market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2021, Sun Pharmaceutical Industries Ltd. announced the launch of a novel formulation in cough management - Chericof 12 (Dextromethorphan Hydrobromide 30 mg and Chlorpheniramine Maleate 4 mg) in India. Chericof 12, India's first prescription cough syrup that provides relief for up to 12 hours, is made with Polistirex technology for long-term medication release. Chericof 12 is only for individuals who are six years old or older.
• In 2020, Johnson & Johnson, the pharmaceutical company has developed and marketed various Dextromethorphan-containing products under their brand names, such as Tylenol Cold & Flu and Robitussin. They have focused on product innovation, introducing new formulations and packaging designs to enhance consumer convenience and compliance.

Global Dextromethorphan Market Scope

The global dextromethorphan market is segmented on the basis of product type, age group, dosage form, route of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Over-the-counter (OTC)
• Prescription Drug

Age Group

• Pediatric
• Adult

Dosage Form

• Syrup
• Tablet
• Others

Route of Administration

• Oral
• Others

End Users

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

全球右美沙芬市场区域分析/见解

对全球右美沙芬市场进行了分析，并按国家、产品类型、年龄组、剂型、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

全球右美沙芬市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在全球右美沙芬市场占据主导地位，因为该地区拥有强大的医疗设施基础、主要市场参与者的强大影响力以及不断增加的研究活动。   

预计在 2023 年至 2030 年的预测期内，亚太地区将见证全球右美沙芬市场的显著增长，这得益于该地区政府加强宣传力度、医疗设施增加、研究活动增多、拥有大量未开发市场、人口众多以及对优质医疗服务的需求不断增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

全球右美沙芬市场还为您提供每个国家/地区资本设备医疗保健支出增长、全球右美沙芬市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对全球右美沙芬市场的影响的详细市场分析。数据适用于 2015-2020 年的历史时期。

竞争格局和全球右美沙芬市场份额分析

全球右美沙芬市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球右美沙芬市场的关注有关。

全球右美沙芬市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司（英国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司 (印度)
• Zydus 集团 (印度)
• 卡迪拉（印度）
• Aurobindo Pharma（印度）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Intas Pharmaceuticals Ltd.（印度）
• Amneal Pharmaceuticals LLC.（美国）
• Cipla Inc.（美国）
• Hikma Pharmaceuticals PLC（英国）
• 3M（美国）
• 拜耳公司（德国）
• Ipca Laboratories Ltd.（印度）
• Unique Pharmaceuticals Limited.（印度）
• Aceto（美国）

SKU-68164